Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
About Artivion, Inc. (NYSE: AORT)
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a prominent medical device company dedicated to developing elegant and straightforward solutions addressing the complex challenges faced by cardiac and vascular surgeons in treating aortic diseases. The company offers a wide array of aortic-centric products, including aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, distributed in over 100 countries worldwide.
Recent Achievements and Financial Performance:
- For the third quarter of 2023, Artivion reported revenues of $87.9 million, marking a 14% increase year-over-year, with notable growth in aortic stent grafts and On-X mechanical heart valves.
- Completed enrollment in the PERSEVERE clinical trial, targeting PMA approval for the AMDS Hybrid Prosthesis by 2025, showcasing significant reductions in all-cause mortality and major adverse events.
- Announced a comprehensive $350 million non-dilutive credit agreement to address debt maturities and further optimize the capital structure, highlighting the company's strategic growth initiatives.
Product Innovation and Clinical Trials:
- The On-X Aortic Heart Valve Low INR post-market study demonstrated superior patient outcomes, significantly reducing major bleeding events compared to historic controls.
- Artivion's product portfolio includes innovative solutions like the AMDS Hybrid Prosthesis, aimed at improving outcomes for patients with acute DeBakey Type I aortic dissections.
With a strong focus on clinical efficacy and market expansion, Artivion continues to be a pivotal player in the cardiac and vascular surgery market, striving to deliver life-saving products and technologies that improve patient outcomes.
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) announces participation in Stifel 2023 Healthcare Conference on November 15, 2023, and Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 16, 2023. Management will present at the Lotte New York Palace and host one-on-one meetings, providing insights into the company's cardiac and vascular surgery focus on aortic disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
-
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) announced its financial results for Q3 2023. The company achieved revenue of $87.9 million, a 14% increase on a GAAP basis and 12% increase on a non-GAAP constant currency basis compared to Q3 2022. Non-GAAP adjusted EBITDA increased 34% to $13.9 million. Aortic stent graft revenues increased 30% and On-X revenues increased 14% compared to Q3 2022. The company is nearing completion of enrollment in the PERSEVERE clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.88%
Tags
-
Rhea-AI Summary
Artivion, Inc. to release third quarter 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
Rhea-AI Summary
Artivion announces positive results from On-X Aortic Heart Valve study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.71%
Tags
-
Rhea-AI Summary
Interim data shows significant reduction in all-cause mortality with AMDS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.71%
Tags
-
Rhea-AI Summary
Artivion, Inc. to present at Deutsche Bank conference on October 3, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
Rhea-AI Summary
Artivion, Inc. to present at Gilmartin Group Emerging Growth Company Showcase on September 21, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
-
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) will participate in three upcoming investor conferences. They will present at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023, and participate in investor meetings at the Needham Virtual MedTech & Diagnostics 1x1 Conference on August 14, 2023, and the UBS MedTech, Tools, and Genomics Summit on August 16, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
FAQ
What is the current stock price of Artivion (AORT)?
The current stock price of Artivion (AORT) is $28.48 as of December 20, 2024.
What is the market cap of Artivion (AORT)?
The market cap of Artivion (AORT) is approximately 1.2B.
What products does Artivion, Inc. offer?
Artivion's product portfolio includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues.
Where is Artivion, Inc. headquartered?
Artivion is headquartered in suburban Atlanta, Georgia.
What are some recent clinical achievements of Artivion?
Recent achievements include superior results from the On-X Aortic Heart Valve Low INR post-market study and the completion of enrollment in the PERSEVERE clinical trial for the AMDS Hybrid Prosthesis.
What was Artivion's revenue growth in the third quarter of 2023?
Artivion achieved a revenue of $87.9 million in the third quarter of 2023, marking a 14% increase year-over-year.
How is Artivion addressing its debt maturities?
Artivion announced a comprehensive $350 million non-dilutive credit agreement to address debt maturities and optimize its capital structure.
In how many countries does Artivion market its products?
Artivion markets and sells its products in over 100 countries worldwide.
What is the focus of Artivion's clinical trials?
Artivion's clinical trials focus on developing products like the AMDS Hybrid Prosthesis to improve outcomes in treating aortic dissections and other aortic diseases.
What are the key products in Artivion's portfolio?
Key products include the On-X mechanical heart valves, aortic stent grafts, surgical sealants, and implantable cardiac and vascular human tissues.
What are the benefits of the On-X Aortic Heart Valve?
The On-X Aortic Heart Valve has demonstrated a significant reduction in major bleeding events, offering improved patient outcomes.
When does Artivion expect to achieve PMA approval for the AMDS Hybrid Prosthesis?
Artivion anticipates PMA approval for the AMDS Hybrid Prosthesis by 2025, following the successful completion of the PERSEVERE clinical trial.
Artivion, Inc.
NYSE:AORT
AORT Rankings
AORT Stock Data
1.17B
36.71M
5.51%
87.55%
7.67%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States of America
KENNESAW